glp 1 agonist australia Market Overview: GLP-1 Agonists and the Obesity Market | Blog New warnings for weight loss

Description

PMID: 38806481

These findings help address ongoing safety concerns surrounding this widely prescribed class of medications

The incretin-based mechanism of action for these agents causes them to suppress glucagon in a glucose-dependent fashion while simultaneously inducing insulin secretion

Foxa2), paired box protein 2 (Pax2), neuronal differentiation factor 1/beta 2 (NeuroD/Beta2), and basic helix-loop-helix transcription factor E47 with the G1, G2, G3, or G4 elements (Figure 2) [100,102,104,106,[110], [111], [112], [113], [114], [115], [116], [117], [118]]

Its also important to screen for any history of eating disorders, as the appetite-suppressing effects of GLP-1s may pose risks for certain individuals